2013年排名前13位HIV和肝炎的故事

StephenW

Top 13 HIV and Hepatitis Stories of 2013

    Print   
    Email   

Details
    Category: HIV Treatment   
    Published on Monday, 30 December 2013 00:00
    Written by Liz Highleyman

10. Long-term Benefits of Hepatitis B Treatment

The top hepatitis B story for 2013 remains the same as for 2012 -- the growing body of evidence showing that long-term nucleoside/nucleotide antiviral therapy can reduce detrimental outcomes including cirrhosis, liver cancer, and liver-related death.

At this year's AASLD Liver Meeting researchers reported that long-term treatment with entecavir (Baraclude) or tenofovir (Viread) can reduce -- but not eliminate -- the likelihood that people with chronic hepatitis B will develop hepatocellular carcinoma. Arelated report presented at the EASL International Liver Congress showed that long-term tenofovir begins to significantly lower the risk of liver cancer after about 5 years.

Other studies reported this year showed that antiretroviral therapy using drugs like tenofovir that are dually active against both HIV and HBV helps protect against hepatitis B infection, while tenofovir may also help prevent mother-to-child HBV transmission. Finally, a study presented at the EASL meeting showed that Truvada (tenofovir + emtricitabine) is more effective than tenofovir alone against immune-tolerant hepatitis B -- but it remains unclear whether such individuals need treatment.

2013年排名前13位HIV和肝炎的故事

    打印
    电子邮件

详细信息
    类别： HIV治疗
    在本周一发布，二○一三年十二月三十○日00:00
    写由Liz Highleyman

10 。乙肝治疗的长期利益

顶乙型肝炎的故事在2013年保持不变，为2012  - 证据越来越多，显示长期核苷/核苷酸抗病毒治疗可以减少有害的结果，包括肝硬化，肝癌和肝相关死亡。

在今年的美国肝病学会肝癌会议的研究人员报告说，恩替卡韦（博路定）或替诺福韦（ Viread的）长期治疗可降低 - 但不能消除 - 即患有慢性乙型肝炎患者将发展为肝细胞癌的可能性。在EASL国际肝病会议提出Arelated报告显示，长期替诺福韦开始后约5年来显著降低肝癌的风险。

其他的研究报告显示，今年，使用药物如替诺福韦是对HIV和HBV双重抗逆转录病毒治疗有助于预防乙肝病毒感染，而替诺福韦也可能有助于防止母亲HBV母婴传播。最后，在欧洲肝病学会会议上提出的一项研究显示， Truvada的（替诺福韦+恩曲他滨）比单独替诺福韦抗免疫耐受乙肝更有效 - 但目前还不清楚是否这些个人需要治疗。